Europe Antimicrobial Susceptibility Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Antimicrobial Susceptibility Testing  Market Segmentation, By Product Type (Instruments, Consumables & Accessories & Services & Software), Methods (Mass Spectrometry Method, Dilution, Disk Diffusion, E-Test, Genotypic Methods & Others),  Type (Antibacterial Testing, Antifungal Testing & Rapid-AST),  Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology & Others),  End User (Hospitals, Pharmaceuticals and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, Research Centres and Academic Institutes & Others),  Distribution Channel (Direct Sales, Retail Sales & Third Party Distributor) - Industry Trends and Forecast to 2033

Europe Antimicrobial Susceptibility Testing Market Size

• The Europe Antimicrobial Susceptibility Testing Market size was valued at USD 1.32 billion in 2025 and is expected to reach USD 2.01 billion by 2033, at a CAGR of 5.40% during the forecast period
• The market growth is largely fueled by the increasing prevalence of infectious diseases and the rising global concern regarding antimicrobial resistance, leading to greater demand for advanced diagnostic solutions in hospitals, laboratories, and research institution
• Furthermore, growing demand for rapid, accurate, and automated diagnostic tools for identifying effective antibiotic treatments is establishing antimicrobial susceptibility testing as an essential component of modern clinical microbiology. These converging factors are accelerating the uptake of Antimicrobial Susceptibility Testing solutions, thereby significantly boosting the industry's growth

Europe Antimicrobial Susceptibility Testing Market Analysis

• Antimicrobial susceptibility testing, used to determine the effectiveness of antibiotics against specific microorganisms, is becoming an essential component of modern clinical microbiology and infectious disease management across hospitals, diagnostic laboratories, and research institutions due to its ability to guide precise antimicrobial therapy and improve patient outcomes
• The escalating demand for antimicrobial susceptibility testing is primarily fueled by the rising global burden of infectious diseases, growing concerns regarding antimicrobial resistance (AMR), and the increasing need for rapid and accurate diagnostic tools to support effective treatment decisions
• U.K. dominated the Europe Antimicrobial Susceptibility Testing Market with the largest revenue share of approximately 41.6% in 2025, characterized by advanced healthcare infrastructure, high adoption of automated diagnostic technologies, and a strong presence of key industry players
• Germany is expected to be the fastest growing region in the Europe Antimicrobial Susceptibility Testing Market during the forecast period due to increasing healthcare expenditure, rising prevalence of infectious diseases, expanding diagnostic laboratory networks, and growing government initiatives to combat antimicrobial resistance
• The antibacterial testing segment dominated the largest market revenue share of 52.7% in 2025, driven by the high global prevalence of bacterial infections such as pneumonia, urinary tract infections, and bloodstream infections

Report Scope and Europe Antimicrobial Susceptibility Testing Market Segmentation

Europe Antimicrobial Susceptibility Testing Market Trends

“Increasing Adoption of Automated and Rapid Diagnostic Technologies”

• A significant and accelerating trend in the Antimicrobial Susceptibility Testing (AST) market is the growing adoption of automated and rapid diagnostic technologies that enable faster and more accurate detection of antimicrobial resistance. Healthcare systems across Europe are increasingly prioritizing advanced diagnostic solutions to support effective infection management and improve patient outcome
• For instance, bioMérieux introduced advanced automated AST systems such as the VITEK platform, which is widely used in European clinical laboratories to rapidly identify bacterial pathogens and determine their antibiotic susceptibility profiles, significantly reducing diagnostic turnaround time
• Rapid AST technologies are becoming essential for supporting antimicrobial stewardship programs across hospitals and healthcare facilities. By enabling clinicians to identify the most effective antibiotics in a shorter time frame, these technologies help reduce unnecessary antibiotic usage and minimize the risk of antimicrobial resistance
• In addition, the integration of digital laboratory systems and data management platforms is improving laboratory workflow efficiency and enabling better data sharing between diagnostic laboratories and healthcare providers
• Increasing investments in diagnostic infrastructure, along with ongoing research and development activities in microbiology diagnostics, are further strengthening the adoption of innovative antimicrobial susceptibility testing solutions
• As healthcare providers continue to focus on early detection of resistant pathogens and improved infection control strategies, the demand for advanced antimicrobial susceptibility testing technologies is expected to grow significantly in the coming years

Europe Antimicrobial Susceptibility Testing Market Dynamics

Driver

“Rising Prevalence of Antimicrobial Resistance and Infectious Diseases”

• The increasing prevalence of antimicrobial resistance (AMR) and infectious diseases is a major factor driving the demand for antimicrobial susceptibility testing across healthcare systems. Accurate identification of pathogen resistance patterns is critical for selecting appropriate antibiotic treatments and preventing the spread of resistant infections
• For instance, according to initiatives supported by the European Centre for Disease Prevention and Control (ECDC), hospitals across Europe are strengthening microbiology diagnostic capabilities and implementing antimicrobial stewardship programs to monitor antibiotic resistance trends and guide treatment decisions
• Healthcare providers are increasingly relying on AST technologies to support clinical decision-making by identifying effective antimicrobial therapies for patients suffering from bacterial infections
• The growing incidence of hospital-acquired infections (HAIs) and multidrug-resistant organisms has further increased the need for reliable and rapid susceptibility testing in hospitals and diagnostic laboratories
• In addition, government initiatives, public health surveillance programs, and global collaborations aimed at combating antimicrobial resistance are encouraging healthcare institutions to invest in advanced diagnostic solutions
• As awareness regarding antimicrobial resistance continues to rise, the demand for accurate and efficient antimicrobial susceptibility testing systems is expected to expand steadily across hospitals, diagnostic laboratories, and research institutions

Restraint/Challenge

“High Cost of Advanced Diagnostic Systems and Limited Laboratory Infrastructure”

• One of the key challenges affecting the growth of the Europe Antimicrobial Susceptibility Testing Market is the high cost associated with advanced diagnostic instruments, automated testing systems, and specialized laboratory equipment required for microbiology testing
• For instance, the installation and maintenance of automated AST systems in smaller hospitals or diagnostic laboratories can be financially challenging, particularly for healthcare facilities with limited budgets and infrastructure
• In addition, antimicrobial susceptibility testing requires skilled laboratory personnel and specialized training to accurately interpret test results and maintain laboratory quality standards
• Limited laboratory infrastructure in certain regions and smaller healthcare facilities may restrict the widespread adoption of advanced AST technologies
• Furthermore, delays in regulatory approvals and strict compliance requirements for diagnostic devices can slow down the introduction of new testing technologies into the market
• Addressing these challenges through improved healthcare investments, training programs for laboratory professionals, and the development of cost-effective diagnostic solutions will be essential for supporting the long-term growth of the Europe Antimicrobial Susceptibility Testing Market

Europe Antimicrobial Susceptibility Testing Market Scope

The Europe Antimicrobial Susceptibility Testing Market is segmented on the basis of product type, methods, type, application, end user, and distribution channel.

• By Product Type

On the basis of product type, the Europe Antimicrobial Susceptibility Testing Market is segmented into instruments, consumables & accessories, services, and software. The consumables & accessories segment dominated the largest market revenue share of 48.2% in 2025, driven by the high and recurring demand for reagents, culture media, antibiotic panels, and testing kits used in antimicrobial susceptibility testing procedures. These consumables are essential for routine laboratory testing and must be replenished frequently, making them a consistent revenue-generating component of the market. Increasing cases of infectious diseases and the rising global burden of antimicrobial resistance are significantly increasing the number of susceptibility tests performed worldwide. In addition, hospitals and diagnostic laboratories rely heavily on consumables for accurate microbial identification and antibiotic effectiveness testing. The growing expansion of diagnostic laboratories and increasing adoption of automated testing platforms are further driving demand for consumables. Furthermore, continuous product launches and improvements in reagent formulations are also supporting the growth of this segment.

The instruments segment is expected to witness the fastest CAGR of 10.6% from 2026 to 2033, driven by the increasing adoption of automated antimicrobial susceptibility testing systems in clinical laboratories. Advanced instruments enable faster and more accurate identification of pathogens and antibiotic resistance patterns. Healthcare facilities are increasingly investing in automated AST instruments to improve laboratory efficiency and reduce turnaround time for test results. Technological advancements such as integrated diagnostic platforms and artificial intelligence-enabled systems are further improving testing accuracy. In addition, growing investments in healthcare infrastructure and laboratory automation are encouraging laboratories to upgrade to advanced AST instruments. The increasing focus on rapid diagnostics and early infection detection is also contributing to the rapid growth of this segment.

• By Methods

On the basis of methods, the Europe Antimicrobial Susceptibility Testing Market is segmented into mass spectrometry method, dilution, disk diffusion, E-test, genotypic methods, and others. The disk diffusion segment dominated the largest market revenue share of 36.5% in 2025, driven by its widespread use as a standard and cost-effective method for antimicrobial susceptibility testing. Disk diffusion testing is commonly used in clinical microbiology laboratories due to its simplicity, reliability, and affordability. The method involves placing antibiotic-impregnated disks on agar plates inoculated with bacteria to determine antibiotic effectiveness. Many laboratories worldwide rely on disk diffusion testing because it does not require expensive equipment and can deliver reliable results for routine testing. In addition, standard guidelines provided by clinical organizations further support its widespread adoption. Increasing diagnostic testing volumes in hospitals and laboratories are further contributing to the dominance of this segment.

The genotypic methods segment is expected to witness the fastest CAGR of 11.4% from 2026 to 2033, driven by the growing adoption of molecular diagnostic technologies. Genotypic testing identifies genetic markers associated with antimicrobial resistance, allowing rapid and precise detection of resistant pathogens. Advances in polymerase chain reaction (PCR), next-generation sequencing, and molecular diagnostic platforms are significantly improving the accuracy and speed of susceptibility testing. Healthcare providers increasingly prefer genotypic methods because they can deliver results faster than traditional culture-based methods. In addition, the rising focus on personalized medicine and targeted antimicrobial therapies is supporting the adoption of molecular diagnostic techniques. Increasing research activities and government initiatives to combat antimicrobial resistance are further accelerating the growth of this segment.

• By Type

On the basis of type, the Europe Antimicrobial Susceptibility Testing Market is segmented into antibacterial testing, antifungal testing, and rapid-AST. The antibacterial testing segment dominated the largest market revenue share of 52.7% in 2025, driven by the high global prevalence of bacterial infections such as pneumonia, urinary tract infections, and bloodstream infections. Antibacterial susceptibility testing is essential for determining the effectiveness of antibiotics against bacterial pathogens. Hospitals and diagnostic laboratories routinely perform antibacterial testing to guide physicians in selecting appropriate antibiotic treatments. The growing concern over antibiotic resistance and the increasing misuse of antibiotics are significantly increasing the need for antibacterial susceptibility testing worldwide. In addition, rising hospital-acquired infections and the expansion of microbiology laboratories are further supporting the growth of this segment. Continuous advancements in diagnostic technologies are also improving the accuracy and efficiency of antibacterial testing.

The rapid-AST segment is expected to witness the fastest CAGR of 12.3% from 2026 to 2033, driven by the increasing demand for faster diagnostic solutions to combat antimicrobial resistance. Rapid antimicrobial susceptibility testing technologies significantly reduce the time required to determine the appropriate antibiotic therapy. These systems enable healthcare providers to initiate targeted treatment quickly, improving patient outcomes and reducing hospital stays. Advances in microfluidics, molecular diagnostics, and automated testing platforms are accelerating the development of rapid AST technologies. In addition, healthcare systems worldwide are focusing on improving diagnostic speed to prevent the spread of drug-resistant infections. Increasing investments in rapid diagnostic technologies and the growing adoption of point-of-care testing solutions are further supporting the rapid growth of this segment.

• By Application

On the basis of application, the Europe Antimicrobial Susceptibility Testing Market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and others. The clinical diagnostics segment dominated the largest market revenue share of 47.9% in 2025, driven by the growing number of infectious disease cases requiring laboratory testing for accurate diagnosis and treatment. Hospitals and diagnostic laboratories rely heavily on antimicrobial susceptibility testing to determine the most effective antibiotics for treating infections. The increasing prevalence of hospital-acquired infections and antibiotic-resistant pathogens is significantly boosting the demand for clinical diagnostic testing. In addition, governments and healthcare organizations worldwide are implementing antimicrobial stewardship programs to promote responsible antibiotic use. The expansion of diagnostic laboratories and improvements in microbiology testing technologies are further supporting the growth of this segment.

The drug discovery and development segment is expected to witness the fastest CAGR of 10.8% from 2026 to 2033, driven by the growing need to develop new antibiotics and antimicrobial agents. Pharmaceutical and biotechnology companies are actively investing in research to combat antimicrobial resistance and develop next-generation antimicrobial therapies. Antimicrobial susceptibility testing plays a critical role in evaluating the effectiveness of new drug candidates during preclinical and clinical trials. In addition, increasing government funding and collaborations between research institutions and pharmaceutical companies are supporting antimicrobial research activities. The rising global threat of drug-resistant infections is further encouraging pharmaceutical companies to accelerate antibiotic development programs.

• By End User

On the basis of end user, the Europe Antimicrobial Susceptibility Testing Market is segmented into hospitals, pharmaceuticals and biotechnology companies, diagnostic laboratories, contract research organizations, research centres and academic institutes, and others. The diagnostic laboratories segment dominated the largest market revenue share of 39.6% in 2025, driven by the high volume of microbial testing performed in specialized laboratories. Diagnostic laboratories serve as primary centers for conducting antimicrobial susceptibility tests for hospitals and clinics. The increasing demand for accurate infection diagnosis and the rising prevalence of antibiotic-resistant bacteria are boosting the number of tests conducted in these laboratories. In addition, the availability of advanced microbiology instruments and skilled laboratory professionals is supporting the growth of this segment. Expanding laboratory networks and increasing healthcare investments worldwide are also contributing to the dominance of diagnostic laboratories in this market.

The pharmaceuticals and biotechnology companies segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, driven by increasing research and development activities focused on new antimicrobial drug development. Pharmaceutical companies rely on antimicrobial susceptibility testing to evaluate the effectiveness of drug candidates against various pathogens. The growing global threat of antimicrobial resistance is encouraging pharmaceutical companies to invest heavily in antibiotic discovery and development. In addition, collaborations between biotechnology firms, research institutions, and healthcare organizations are accelerating antimicrobial research programs. The increasing number of clinical trials for new antibiotics and antimicrobial therapies is further supporting the rapid growth of this segment.

• By Distribution Channel

On the basis of distribution channel, the Europe Antimicrobial Susceptibility Testing Market is segmented into direct sales, retail sales, and third-party distributors. The direct sales segment dominated the largest market revenue share of 51.4% in 2025, driven by the strong presence of major diagnostic companies selling instruments and consumables directly to hospitals and laboratories. Direct sales channels allow manufacturers to build strong relationships with healthcare institutions and provide technical support and training services. Many large hospitals and diagnostic laboratories prefer direct procurement from manufacturers to ensure product quality and after-sales support. In addition, direct sales help companies maintain better pricing control and supply chain efficiency. The increasing demand for advanced diagnostic instruments and laboratory automation solutions is further strengthening the dominance of this segment.

The third-party distributor segment is expected to witness the fastest CAGR of 9.6% from 2026 to 2033, driven by the expanding global reach of diagnostic companies through distribution partnerships. Third-party distributors play an important role in supplying diagnostic products to smaller hospitals, clinics, and laboratories, particularly in emerging markets. These distributors help manufacturers expand their market presence without establishing direct sales networks in every region. In addition, growing healthcare infrastructure in developing countries is increasing the demand for diagnostic products supplied through distributor networks. The increasing number of partnerships between diagnostic companies and regional distributors is further supporting the growth of this segment.

Europe Antimicrobial Susceptibility Testing Market Regional Analysis

• The Europe antimicrobial susceptibility testing (AST) market is projected to expand at a substantial CAGR throughout the forecast period, driven by increasing awareness of antimicrobial resistance, growing prevalence of infectious diseases, and the rising adoption of automated diagnostic technologies
• Hospitals, diagnostic laboratories, and research institutions are investing in advanced AST solutions to improve pathogen identification, optimize antibiotic therapies, and enhance patient outcomes. The market growth is further supported by government initiatives promoting antimicrobial stewardship, public health surveillance programs, and strategic collaborations aimed at combating antibiotic resistance across the region
• In addition, the emphasis on rapid and accurate diagnostics in healthcare facilities is driving demand for high-throughput and automated AST platforms, enabling faster turnaround times and more reliable results

U.K. Europe Antimicrobial Susceptibility Testing Market Insight

The U.K. antimicrobial susceptibility testing (AST) market dominated the European region with the largest revenue share of approximately 41.6% in 2025. The market is characterized by advanced healthcare infrastructure, widespread adoption of automated diagnostic systems, and the strong presence of key industry players offering comprehensive AST solutions. Growing investment in hospital and laboratory diagnostics, coupled with increasing awareness of antimicrobial resistance among clinicians and policymakers, is fueling the demand for high-precision AST systems. Furthermore, the expansion of clinical microbiology laboratories and adoption of high-throughput testing platforms are enabling efficient management of bacterial infections and enhancing the country’s antimicrobial stewardship initiatives.

Germany Europe Antimicrobial Susceptibility Testing Market Insight

The Germany antimicrobial susceptibility testing (AST) market is expected to be the fastest-growing in Europe during the forecast period. Growth is supported by rising healthcare expenditure, increasing prevalence of infectious diseases, and expanding networks of diagnostic laboratories. The German government’s strong focus on combating antimicrobial resistance through strategic initiatives and funding programs is further boosting market adoption. In addition, the country’s well-developed healthcare infrastructure, emphasis on innovation, and integration of automated diagnostic technologies in hospitals and research institutions are enabling faster and more reliable susceptibility testing. The increasing demand for cost-effective, accurate, and rapid AST solutions, particularly in clinical and research settings, is expected to drive sustained growth in Germany.

Europe Antimicrobial Susceptibility Testing Market Share

The Antimicrobial Susceptibility Testing industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)

• BD (U.S.)

• bioMérieux S.A. (France)

• Danaher Corporation (U.S.)

• Bruker Corporation (U.S.)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Abbott Laboratories (U.S.)

• Accelerate Diagnostics, Inc. (U.S.)

• Liofilchem S.r.l. (Italy)

• Hardy Diagnostics (U.S.)

• MERLIN Diagnostika GmbH (Germany)

• HiMedia Laboratories Pvt. Ltd. (India)

• Alifax S.r.l. (Italy)

• Creative Diagnostics (U.S.)

• QuidelOrtho Corporation (U.S.)

• Titan Biotech Ltd. (India)

• Mast Group Ltd. (U.K.)

• Autobio Diagnostics Co., Ltd. (China)

• DiaSorin S.p.A. (Italy)

• Bio-Rad Laboratories, Inc. (U.S.)

Latest Developments in Europe Antimicrobial Susceptibility Testing Market

• In June 2021, bioMérieux, a global leader in in-vitro diagnostics, announced a co-exclusive distribution agreement with Specific Diagnostics to commercialize the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Testing (AST) system in Europe. The system enables laboratories to obtain antibiotic susceptibility results directly from positive blood cultures in approximately five hours, significantly accelerating clinical decision-making and supporting antimicrobial stewardship efforts against drug-resistant infections
• In April 2022, COPAN Diagnostics showcased its Colibri automated specimen preparation instrument at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022). The platform automates specimen processing and prepares bacterial suspensions for antimicrobial susceptibility testing, improving laboratory workflow efficiency and supporting faster microbiology diagnostics across European laboratories
• In May 2022, Qualigen Therapeutics announced a strategic agreement to acquire a majority stake in NanoSynex Ltd., a company developing rapid antimicrobial susceptibility testing technologies capable of significantly reducing test turnaround time. The partnership aimed to accelerate commercialization of advanced AST technologies and expand their adoption across global and European clinical microbiology laboratories
• In January 2023, bioMérieux introduced MAESTRIA, an advanced laboratory automation solution designed to streamline microbiology workflows including antimicrobial susceptibility testing processes. The platform improves laboratory efficiency by integrating sample preparation, inoculation, incubation, and reading processes into a fully automated microbiology laboratory ecosystem
• In June 2023, Sysmex Corporation launched the PA-100 AST System in Europe, a rapid point-of-care antimicrobial susceptibility testing platform capable of detecting bacteria and assessing antibiotic effectiveness from urine samples within approximately 30 minutes. The system utilizes proprietary microfluidic technology to significantly reduce testing time compared with conventional culture-based AST methods, enabling faster clinical treatment decisions for infections such as urinary tract infections
• In June 2024, bioMérieux announced regulatory progress for its VITEK REVEAL AST system, a rapid phenotypic antimicrobial susceptibility testing platform designed to deliver results directly from positive blood cultures in around six hours. The technology strengthens the company’s microbiology diagnostics portfolio and supports improved antimicrobial stewardship programs globally, including across European healthcare laboratories

SKU-25671